Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1688-1694

  Moore, Malcolm J ^a   Hirte, H W ^b   Siu, L ^a   Oza, A ^a   Hotte, S J ^b   Petrenciuc, O ^c   Cihon, F ^d   Lathia, C ^d   Schwartz, B ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Bayer Inc   (Canada)

^d BAYER CORPORATION   (United States)

Author keywords

BAY 43 9006; Pharmacokinetics; Phase I; Safety

Indexed keywords

RAF PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER CLASSIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; ENZYME INHIBITION; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HOT FLUSH; HUMAN; LETHARGY; LIVER DYSFUNCTION; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAIL DISEASE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN MANIFESTATION; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; BENZENESULFONATES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES;

EID: 27144527372     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi310     Document Type: Article

References (24)

1. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-4689.
2. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
3. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
4. Doanes AM, Hegland DD, Sethi R et al. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999; 255: 545-548.
5. Lokker NA, Sullivan CM, Hollenbach SJ et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62: 3729-3735.
6. Chen J, Fujii K, Zhang L et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001; 98: 7783-7788.
7. Troppmair J, Rapp UR. Raf and the road to cell survival: A tale of bad spells, ring bearers and detours. Biochem Pharmacol 2003; 66: 1341-1345.
8. Ramirez DM, Rodriguez-Gonzalez A, Lacal JC. Targeting new anticancer drugs within signalliqg pathways regulated by the Ras GTPase superfamily. Int J Oncol 2001; 19: 5-17.
9. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS et al. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 2000; 88: 229-279.
10. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
11. Wilhelm S, Chien DS. BAY 43-9006: Preclinical data. Curr Pharm Des 2002; 8: 2255-2257.
12. Gianpaolo-Ostravage C, Carter C, Hibner B et al. Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models. Proc Am Assoc Cancer Res 2001; 42: (Abstr 4954).
13. Lyons JF, Wilhelm S, Hibner B et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8: 219-225.
14. Villegas G, Lange-Sperandio B, Tufro A. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int 2005; 67: 449-457.
15. Dasgupta P, Sun J, Wang S et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004; 24: 9527-9541.
16. Strumberg D, Awada A, Piccart P et al. Final report of the multiple single agent phase I clinical trials of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22: (Abstr 813).
17. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
20. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
21. Na X, Wu G, Ryan CK et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003; 170: 588-592.
22. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
23. Rak J, Mitsuhashi Y, Sheehan C et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000; 60: 490-498.
24. Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333: 267-283.